Open AccessChemoresponse Assay in Head and Neck Cancer Patients: A Three-Year Follow Up
Author(s) -
Basem T. Jamal,
Gregory A. Grillone,
Scharukh Jalisi
Publication year - 2017
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2017/24802.9816
Subject(s) - medicine , head and neck cancer , chemotherapy , oncology , head and neck , head and neck squamous cell carcinoma , cancer , basal cell , toxicity , radiation therapy , induction chemotherapy , surgery
The majority of patients with advanced head and neck cancer receiving chemotherapy show partial response or frank resistance. Therefore, assessing the individuals' tumour reactivity to the eligible chemotherapeutic compounds carries the potential of personalizing the patient treatment and minimizing ineffective regimens which lead to excess toxicity and cost, treatment delays and possibly causing the tumour to be cross resistant to additional drugs.